178 related articles for article (PubMed ID: 15239652)
1. Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors.
Terasaka T; Kinoshita T; Kuno M; Seki N; Tanaka K; Nakanishi I
J Med Chem; 2004 Jul; 47(15):3730-43. PubMed ID: 15239652
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors.
Terasaka T; Okumura H; Tsuji K; Kato T; Nakanishi I; Kinoshita T; Kato Y; Kuno M; Seki N; Naoe Y; Inoue T; Tanaka K; Nakamura K
J Med Chem; 2004 May; 47(11):2728-31. PubMed ID: 15139750
[TBL] [Abstract][Full Text] [Related]
3. Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: predicting enzyme conformational change and metabolism.
Terasaka T; Tsuji K; Kato T; Nakanishi I; Kinoshita T; Kato Y; Kuno M; Inoue T; Tanaka K; Nakamura K
J Med Chem; 2005 Jul; 48(15):4750-3. PubMed ID: 16033254
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists.
Blum CA; Zheng X; De Lombaert S
J Med Chem; 2004 Apr; 47(9):2318-25. PubMed ID: 15084130
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
[TBL] [Abstract][Full Text] [Related]
6. A highly potent non-nucleoside adenosine deaminase inhibitor: efficient drug discovery by intentional lead hybridization.
Terasaka T; Kinoshita T; Kuno M; Nakanishi I
J Am Chem Soc; 2004 Jan; 126(1):34-5. PubMed ID: 14709046
[TBL] [Abstract][Full Text] [Related]
7. Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4-d]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modeling studies.
Da Settimo F; Primofiore G; La Motta C; Taliani S; Simorini F; Marini AM; Mugnaini L; Lavecchia A; Novellino E; Tuscano D; Martini C
J Med Chem; 2005 Aug; 48(16):5162-74. PubMed ID: 16078836
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of antibacterial AccC inhibitors.
Cheng CC; Shipps GW; Yang Z; Sun B; Kawahata N; Soucy KA; Soriano A; Orth P; Xiao L; Mann P; Black T
Bioorg Med Chem Lett; 2009 Dec; 19(23):6507-14. PubMed ID: 19875284
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.
Wang L; Wang GT; Wang X; Tong Y; Sullivan G; Park D; Leonard NM; Li Q; Cohen J; Gu WZ; Zhang H; Bauch JL; Jakob CG; Hutchins CW; Stoll VS; Marsh K; Rosenberg SH; Sham HL; Lin NH
J Med Chem; 2004 Jan; 47(3):612-26. PubMed ID: 14736242
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
11. Effect of a chemical modification on the hydrated adenosine intermediate produced by adenosine deaminase and a model reaction for a potential mechanism of action of 5-aminoimidazole ribonucleotide carboxylase.
Groziak MP; Huan ZW; Ding H; Meng Z; Stevens WC; Robinson PD
J Med Chem; 1997 Oct; 40(21):3336-45. PubMed ID: 9341908
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
Quan ML; Lam PY; Han Q; Pinto DJ; He MY; Li R; Ellis CD; Clark CG; Teleha CA; Sun JH; Alexander RS; Bai S; Luettgen JM; Knabb RM; Wong PC; Wexler RR
J Med Chem; 2005 Mar; 48(6):1729-44. PubMed ID: 15771420
[TBL] [Abstract][Full Text] [Related]
13. (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor.
Bell MG; Gernert DL; Grese TA; Belvo MD; Borromeo PS; Kelley SA; Kennedy JH; Kolis SP; Lander PA; Richey R; Sharp VS; Stephenson GA; Williams JD; Yu H; Zimmerman KM; Steinberg MI; Jadhav PK
J Med Chem; 2007 Dec; 50(26):6443-5. PubMed ID: 18038968
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of adenosine deaminase by novel 5:7 fused heterocycles containing the imidazo[4,5-e][1,2,4]triazepine ring system: a structure-activity relationship study.
Reayi A; Hosmane RS
J Med Chem; 2004 Feb; 47(4):1044-50. PubMed ID: 14761206
[TBL] [Abstract][Full Text] [Related]
15. Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.
Biftu T; Scapin G; Singh S; Feng D; Becker JW; Eiermann G; He H; Lyons K; Patel S; Petrov A; Sinha-Roy R; Zhang B; Wu J; Zhang X; Doss GA; Thornberry NA; Weber AE
Bioorg Med Chem Lett; 2007 Jun; 17(12):3384-7. PubMed ID: 17433672
[TBL] [Abstract][Full Text] [Related]
16. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs.
Zhang P; Bao L; Zuckett JF; Goldman EA; Jia ZJ; Arfsten A; Edwards S; Sinha U; Hutchaleelaha A; Park G; Lambing JL; Hollenbach SJ; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2004 Feb; 14(4):983-7. PubMed ID: 15013006
[TBL] [Abstract][Full Text] [Related]
18. Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors.
La Motta C; Sartini S; Mugnaini L; Salerno S; Simorini F; Taliani S; Marini AM; Da Settimo F; Lavecchia A; Novellino E; Antonioli L; Fornai M; Blandizzi C; Del Tacca M
J Med Chem; 2009 Mar; 52(6):1681-92. PubMed ID: 19226143
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.
Isaacs RC; Solinsky MG; Cutrona KJ; Newton CL; Naylor-Olsen AM; McMasters DR; Krueger JA; Lewis SD; Lucas BJ; Kuo LC; Yan Y; Lynch JJ; Lyle EA
Bioorg Med Chem Lett; 2008 Mar; 18(6):2062-6. PubMed ID: 18291642
[TBL] [Abstract][Full Text] [Related]
20. The discovery of novel indole-2-carboxamides as cannabinoid CB(1) receptor antagonists.
Cowley PM; Baker J; Barn DR; Buchanan KI; Carlyle I; Clark JK; Clarkson TR; Deehan M; Edwards D; Goodwin RR; Jaap D; Kiyoi Y; Mort C; Palin R; Prosser A; Walker G; Ward N; Wishart G; Young T
Bioorg Med Chem Lett; 2011 Jan; 21(1):497-501. PubMed ID: 21075628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
